You are here: Industry Insights > BioInvent

News List

CASI Pharmaceuticals, BioInvent Gain CTA Approval for BI-1206 contractpharma
December 13, 2021
Phase 1 trials of BI-1206 as a single agent to evaluate the PK/safety profile and in combination with rituximab in NHL.
First person enrolled in Phase I oncolytic virus trial europeanpharmaceuticalreview
March 04, 2021
The Phase I/IIa trial of BT-001 will assess the safety and efficacy of the virus’ dual mode of action in solid tumours.
BioInvent signs monoclonal antibody manufacturing deal with Cantargia pharmaceutical-technology
November 30, 2020
Clinical stage firm BioInvent International and Cantargia have signed a manufacturing agreement for monoclonal antibody CAN10 to treat systemic sclerosis and myocarditis.
BioInvent, CASI Pharmaceuticals Enter Antibody Alliance contractpharma
October 29, 2020
Collaboration accelerates and expands BioInvent's global development plans for BI-1206 in liquid and solid tumors.
BioInvent, Pfizer Extend Immunotherapy Research Term contractpharma
July 02, 2020
Allows the companies to further identify and characterize new targets and antibodies leveraging BioInvent's F.I.R.S.T drug discovery platform.
BioInvent Signs Manufacturing Agreement contractpharma
May 05, 2020
Includes process development and conjugation of two antibodies in BioInvent's labs.
BioInvent Receives TAK-169 IND Application Milestone Payment americanpharmaceuticalreview
July 08, 2019
BioInvent announced it will receive a $0.5 million milestone payment related to the acceptance by the U.S.
Bioinvent Receives IND Approval for Phase I/iia Trial of Anti-fcyriib Antibody americanpharmaceuticalreview
July 04, 2019
BioInvent has received authorization from the U.S. Food and Drug Administration (FDA) to proceed with an Investigational New Drug (IND) application for a Phase I/IIa clinical trial of an immune-modulatory anti-FcγRllB antibody in combination with an anti-
BioInvent receives €0.75 M under Mitsubishi Tanabe Pharma partnership biospectrumasia
April 29, 2019
The license agreement with Mitsubishi Tanabe Pharma covers the development of antibodies from the n-CoDeR antibody library.
BioInvent receives €0.75 M under Mitsubishi Tanabe Pharma partnership biospectrumasia
April 28, 2019
The license agreement with Mitsubishi Tanabe Pharma covers the development of antibodies from the n-CoDeR antibody library.

Previous page 1 2 Next page